{"product_id":"9780727917843","title":"Evaluating Pharmaceuticals for Health Policy and Reimbursement","description":"\u003ch1\u003eEvaluating Pharmaceuticals for Health Policy and Reimbursement\u003c\/h1\u003e \u003ch2\u003eFreemantle, Nick; Hill, Suzanne\u003c\/h2\u003e \u003cp\u003e\u003c\/p\u003e\u003cp\u003e\u003cb\u003e\"The challenge in all settings is to make the difficult decisions in a way that is defensible, justifiable, ethical, and equitable\"\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eSo write Nick Freemantle and Suzanne Hill in their introduction to this important discussion on decision making in the reimbursement of pharmaceuticals. Based around a programme supported by the World Health Organization, chapters by leading academics involved in the research tackle such major issues as international pharmaceutical policy, tensions in licensing policies, priority setting, and relationships between the stakeholders.\u003c\/p\u003e \u003cp\u003eChapters include:\u003c\/p\u003e \u003cul\u003e \u003cli\u003eDevelopment of marketing authorisation procedures for pharmaceuticals\u003c\/li\u003e \u003cli\u003eInterpreting clinical evidence\u003c\/li\u003e \u003cli\u003eInternational pharmaceutical policy: health creation or wealth creation?\u003c\/li\u003e \u003cli\u003eDevelopment of fourth hurdle policies around the world\u003c\/li\u003e \u003cli\u003eEconomic modelling in drug reimbursement\u003c\/li\u003e \u003cli\u003ePriority setting in health care: matching decision criteria with policy objectives\u003c\/li\u003e \u003cli\u003eTensions in licensing and reimbursement decisions: case of riluzole for amytrophic lateral sclerosis\u003c\/li\u003e \u003cli\u003eRelationship between stakeholders: managing the war of words\u003c\/li\u003e \u003cli\u003eMedicine and the media: good information or misleading hype?\u003c\/li\u003e \u003cli\u003eHow to promote quality use of cost-effective medicines\u003c\/li\u003e \u003cli\u003eUsing economic evaluation to inform health policy and reimbursement: making it happen and making it sustainable\u003c\/li\u003e \u003cli\u003ePricing of pharmaceuticals\u003c\/li\u003e \u003cli\u003eEvaluating pharmaceuticals for health policy in low and middle income country settings.\u003c\/li\u003e \u003c\/ul\u003e \u003cp\u003eBesides the controversial issues there is a wealth of practical information including economic modelling and the experiences from the WHO programme, providing readers with workable examples. This is essential reading for clinical researchers in pharmaceuticals and policy makers everywhere.\u003c\/p\u003e \u003ch3\u003eDetails\u003c\/h3\u003e \u003cp\u003ePublished by: BMJ Books\u003c\/p\u003e \u003cp\u003ePublication Date: 2004-09-13\u003c\/p\u003e \u003cp\u003eFormat: Paperback\u003c\/p\u003e \u003cp\u003eISBN-13: 9780727917843\u003c\/p\u003e \u003cp\u003eDOI: \u003c\/p\u003e \u003cp\u003eDimensions: 215.9cm x139.7cm\u003c\/p\u003e \u003cp\u003ePages: 280.0\u003c\/p\u003e ","brand":"Wiley","offers":[{"title":"Default Title","offer_id":44380032303244,"sku":"9780727917843","price":111.56,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0710\/9545\/1788\/files\/9780727917843.jpg?v=1765320907","url":"https:\/\/fh90cf-fv.myshopify.com\/products\/9780727917843","provider":"Late Knight Books and Services, LLC","version":"1.0","type":"link"}